(01) 8899111  info@mcrindustrialengineering.ie

Clients

On July 1, 2014, Actavis (NYSE:ACT) completed the acquisition of Forest Laboratories, creating one of the world’s fastest-growing specialty pharmaceutical companies with annual revenues of more than $15 billion anticipated for 2015. The combination creates a Company with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development and a generic DNA, focused on cost efficiency across the expanded organization.